Arbutus Biopharma Corporation

ABUSNASDAQHealthcare● Active

$4.29

+$0.05(+1.06%)

Market Cap$846449087

P/E Ratio—

52W High$5.1

52W Low$3.04

Avg Volume1.9M

Open$4.29

Beta0.63

Free Cash Flow Financials Revenue

Arbutus Biopharma Corporation (ABUS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ABUS · free cash flow · updated Jun 9, 2026

Core FCF metrics

ABUS · FCF · TTM · margin & CAGR

Free cash flow was −$39.6M for FY2025 (fiscal year ending 2025-12-31), up 39.1% year-over-year The FCF margin was -281.4%.

FY2025 Free Cash Flow−$39.6M▲ +39.1% YoY

Trailing 12M (TTM)−$34.4Mtrailing 4 quarters sum

FCF Margin-281.4%−$39.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ABUS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$39.6M(0M)−$39.6M▲ +39.1%-281.4%

FY2024−$64.8M(0M)−$65.0M▲ +25.2%—

FY2023−$85.9M(1M)−$86.9M▼ 142.4%-479.3%

FY2022−$35.4M(1M)−$35.9M▲ +47.5%-91.9%

FY2021−$67.5M(1M)−$68.3M▼ 32.3%-622.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ABUS · P/FCF · FCF yield · FCF per share

Arbutus Biopharma Corporation (ABUS) reported negative free cash flow of −$0.04B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ABUS · cash flow statement · operating / investing / financing

For FY2025, Arbutus Biopharma Corporation generated −$39.6M in operating cash flow and spent 0M in capital expenditures, yielding −$39.6M in free cash flow.

Operating Activities

−$39.6M

Cash from core business operations

2025-12-31

Investing Activities

+$15.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$5.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$39.6M) − |CapEx| (0M) = FCF (−$39.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ABUS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Arbutus Biopharma CorporationYOU

ABUS

−$39.6M+39.1%-281.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Arbutus Biopharma Corporation (ABUS) reported free cash flow of −$39.6M for FY2025 (fiscal year ending 2025-12-31), up 39.1% year-over-year. The FCF margin was -281.4%.

Based on available data, Arbutus Biopharma Corporation has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $33.3M in FY2012.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ABUS free cash flow · 8 questions

Arbutus Biopharma Corporation free cash flow was −$39.6M for FY2025, up 39.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$34.4M.

ABUS free cash flowABUS FCFABUS FCF 2025ABUS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Arbutus Biopharma Corporation · Arbutus Biopharma Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026